WHEN ADULTS WITH MAC LUNG DISEASE REMAIN CULTURE POSITIVE AFTER 6 MONTHS OF MULTIDRUG THERAPY, Adding ARIKAYCE can change what comes next1,2

with ARIKAYCE, your chance to break the pattern starts here

Adding ARIKAYCE helped patients with MAC lung disease get converted and stay converted.1,3,4

LIMITED POPULATION: ARIKAYCE® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients.


This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.


Limitation of Use: ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.




MAC=Mycobacterium avium complex.

References:
1. ARIKAYCE [package insert]. Bridgewater, NJ: Insmed Incorporated; 2023. 2. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):e1-e36. 3. Griffith DE, Eagle G, Thomson R, et al; CONVERT Study Group. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT): a prospective, open-label, randomized study. Am J Respir Crit Care Med. 2018;198(12):1559-1569. 4. Griffith DE, Thomson R, Flume PA, et al. Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure. Chest. 2021;160(3):831-842.

Visit The ARIKAYCE Academy, an online resource center for education and insights on MAC lung disease featuring experts in the field.

Visit The ARIKAYCE AcademyWhite button caret.
mac lung disease patient

Learn about patients who may be appropriate for adding ARIKAYCE to their multidrug therapy.

mac lung disease test result

See how treatment with ARIKAYCE + multidrug therapy resulted in culture conversion results that lasted.1,3,4

arikayce resource for health care providers

Discover resources to help you and your patients get started with adding ARIKAYCE to multidrug therapy.1